Study of XNW28012 in Subjects With Advanced Solid Tumors Who Failed Standard Treatments
A phase 1/2 trial of XNW28012 in pancreatic ductal adenocarcinoma, ovarian cancer and cervical cancer, run by Evopoint Biosciences Inc., now recruiting.
Overview
Study of XNW28012 in Subjects With Advanced Solid Tumors Who Failed Standard Treatments is a phase 1/2 interventional study registered as NCT06799637 by Evopoint Biosciences Inc., with 350 participants planned, started 2023-12-01 and due to reach its primary completion in 2026-12-31. Interventions recorded: XNW28012.
Similar pages
not linked directly; found by shared links- TrialStudy of XNW28012 in Subjects With Metastatic Pancreatic Cancer Who Received Prior Systemic Therapy
Shares Evopoint Biosciences, Pancreatic ductal adenocarcinoma and the tag pipeline.
- TrialA Study of PARG Inhibitor XNW29016 in Patients With Advanced Solid Tumors Who Failed Standard Treatment
Shares Evopoint Biosciences and the tag pipeline.
- TrialA Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies
Shares Ovarian cancer, Pancreatic ductal adenocarcinoma and the tag pipeline.
- TrialA Study of DM002 in Patients With Advanced Solid Tumors
Shares Ovarian cancer, Pancreatic ductal adenocarcinoma and the tag pipeline.
- TrialStudy to Assess GTAEXS617 in Participants With Advanced Solid Tumors
Shares Ovarian cancer, Pancreatic ductal adenocarcinoma and the tag pipeline.
- TrialEarly Phase Study of KESONOTIDE™in Participants With Solid Tumours
Shares Ovarian cancer, Pancreatic ductal adenocarcinoma and the tag pipeline.
- TrialA Study to Evaluate 9MW2821 Versus Treatment of Physician's Choice for Subjects With Recurrent or Metastatic Cervical Cancer
Shares Cervical cancer and the tag pipeline.
- TrialA Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
Shares Ovarian cancer, Pancreatic ductal adenocarcinoma and the tag pipeline.